{"organizations": [], "uuid": "ffca4f2f88dd1f1276aa40b6d5479368b214c630", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/15/globe-newswire-emerald-health-therapeutics-announces-16-point-8-million-prospectus-sale-concurrent-secondary-sale.html", "country": "US", "domain_rank": 767, "title": "Emerald Health Therapeutics Announces $16.8 Million Prospectus Sale; Concurrent Secondary Sale", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.993, "site_type": "news", "published": "2018-05-15T16:00:00.000+03:00", "replies_count": 0, "uuid": "ffca4f2f88dd1f1276aa40b6d5479368b214c630"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/15/globe-newswire-emerald-health-therapeutics-announces-16-point-8-million-prospectus-sale-concurrent-secondary-sale.html", "ord_in_thread": 0, "title": "Emerald Health Therapeutics Announces $16.8 Million Prospectus Sale; Concurrent Secondary Sale", "locations": [], "entities": {"persons": [], "locations": [{"name": "ctoria", "sentiment": "none"}, {"name": "british columbia", "sentiment": "none"}], "organizations": [{"name": "emerald health therapeutics", "sentiment": "negative"}, {"name": "united states newswire", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}, {"name": "emerald", "sentiment": "none"}, {"name": "emerald health therapeutics, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES\nVICTORIA, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (\"Emerald\" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Investor”) under which the Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 units of the Company (the “Units”) at a price of $4.20 per Unit for total gross proceeds of $16,800,000 (the “Offering”). The securities forming the Units will be qualified under a shelf prospectus supplement to be filed by Emerald prior to closing.\nEach Unit will consist of one common share of the Company and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the Investor to acquire one common share of the Company (a “Warrant Share”) at a price of $5.20 per Warrant Share for a period of eighteen months following the closing of the Offering. If the closing sale price of the Company’s common shares (the “Common Shares”) on the TSX Venture Exchange or other principal exchange upon which the Company’s shares are traded is greater than $6.50 per Common Share for a period of twenty consecutive trading days at any time after the closing of the Offering, the Company may accelerate the expiry date of the Warrants by giving notice to the Investor and in such case the Warrants will expire on the 30th day after the date on which the notice is given by the Company.\nThe Investor has also agreed to purchase from Emerald Health Sciences Inc. (“Sciences”), a control person of the Company, 2,000,000 Common Shares held by Sciences at a price of $4.20 per share (the “Secondary Sale”). The Secondary Sale will close concurrently with the closing of the Offering.\nThe Company intends to use the net proceeds of the Offering to fund the completion of its recently acquired Agro-Biotech facility in Quebec, working capital, and general corporate purposes.\nThe Units and Common Shares to be sold under the Secondary Sale will be offered by way of a shelf prospectus supplement to be filed in all of the provinces of Canada, except Quebec, pursuant to National Instrument 44-101 - Short Form Prospectus Distributions .\nThe closing date of the Offering and Secondary Sale is expected to be on or about May 22, 2018, and is subject to certain conditions including, but not limited to, the Investor being satisfied with the results of its due diligence, no material adverse change in the affairs of the Company, and the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.\nThis press release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any state in which such offer, solicitation, or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933 , as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933 , as amended, and applicable state securities laws.\nAbout Emerald Health Therapeutics, Inc.\nEmerald Health Therapeutics (TSXV:EMH) is a Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations and produces and sells dried cannabis and cannabis oil for medical purposes. Emerald owns 50% of a joint venture with Village Farms International, Inc. that is converting an existing 1.1 million square foot greenhouse in Delta, BC to grow cannabis. It owns a 75,000 square foot indoor facility in St. Eustache, QC and is adding a 500,000 square foot greenhouse in Metro Vancouver to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald Health Therapeutics is part of the Emerald Health group , which includes multiple companies focused on developing cannabis and cannabinoid products with potential wellness and medical benefits.\nPlease visit www.emeraldhealth.ca for more information or contact:\nRob Hill, Chief Financial Officer\n(800) 757 3536 Ext. #5\nRay Lagace, Investor Relations Manager\n(800) 757 3536 Ext. #5\ninvest@emerald.care\nCautionary Statements Regarding Forward Looking Information\nCertain statements in this press release constitute , within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are \" \".\nWe caution you that such \" \" involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, the filing and effectiveness of the prospectus supplement; the use of proceeds from the Offering; the anticipated closing date of the Offering and the Secondary Sale; the development, expansion and conversion of greenhouse facilities; and the starting of adult-use cannabis market in 2018.\nEmerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these except as required by law. These involve risks and uncertainties relating to, among other things, failure to meet the conditions of closing of the Offering; uncertainty with respect to the completion of the Offering; filing of the shelf prospectus supplement; the ability to obtain applicable regulatory approval for the Offering and the Secondary Sale; the ability of the Company to negotiate and complete future funding transactions; variations in market conditions; and other risk factors described in the Prospectus and the Company's other filings with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such .\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\nSource: Emerald Health Therapeutics Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/bc102817-e4d7-42c4-ba4c-b88a9aa9955d", "https://www.globenewswire.com/Tracker?data=fEM3vc2d8mrtK4P8rbuvAmh7WIwKX31DXGTTN8QrClvNYWRRD1Pw3EfJbIIBvkT7qRzCi_JCT1jo1oxpzjlncIWz3MyIQZaDUQGDAeaG_uU=", "https://www.globenewswire.com/Tracker?data=mZ19pzLZVmjR4HZPw7g3ZsKQm1HDJF2UJHLEPPY1yuD5cOLrl9nsd6hdfC_nyVGF7vtFwii8ksUs18VMZxrwqurcn8daXfsgdMCOn-DT5_Y=", "https://www.globenewswire.com/Tracker?data=g6hC8b8gYbmD4Lf0OiYKGpXUhVVZm2BCMXIKtP99C4_ml8vVq9Firprw-J7ZRwQ_oSPHcWxnz5HaUztc7Xra3Q==", "https://www.globenewswire.com/Tracker?data=0I5m199ICKgO1P98NOyioNKE2WB3Y8GJVTiSA3-BkIjh9w6XDc-6qWFEwzRofrLN1aR5hh4zWcX05XyHU3kGYVo-9uPG7ZEcASNYwuzyBpQ="], "published": "2018-05-15T16:00:00.000+03:00", "crawled": "2018-05-15T17:26:44.000+03:00", "highlightTitle": ""}